MEI Pharma urges its shareholders to vote in favor of the pending transaction with Infinity Pharmaceuticals at the upcoming special meeting on July 14, 2023. Proxy advisory firms Glass Lewis and ISS have recommended voting for the transaction, citing the strategic rationale and potential benefits of combining the two companies’ product portfolios. MEI Pharma has mailed a letter to shareholders and emphasized the importance of their vote.
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. The Company noted that leading proxy advisory firm Glass Lewis joined ISS in recommending that shareholders vote FOR the transaction.
MEI issued the following statement:
MEI shareholders have the opportunity to participate in the upside potential of a combined company that is well capitalized and positioned to advance a diversified pipeline of three clinical-stage development programs. With Infinity, we will be well positioned to create value for shareholders and deliver improved therapeutic options for patients. We encourage shareholders to follow the recommendations by leading proxy advisory firms ISS and Glass Lewis and vote FOR the Infinity transaction.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
In making its recommendation, ISS stated in its July 3, 2023 report:1
“The board’s strategic review process appears to have been reasonably thorough and the rationale for the transaction is compelling. The merger will combine the product portfolios of two clinical-stage biotechnology companies, creating a more diversified entity with sufficient cash resources to fund product development through 2025.”
The Company today also mailed a letter to shareholders reminding them to vote FOR the Infinity transaction. The letter has been filed with the Securities and Exchange Commission.
YOUR VOTE IS IMPORTANT!
VOTE “FOR” THE TRANSACTION WITH INFINITY PHARMACEUTICALS TODAY
MEI Pharma has scheduled the special meeting to approve the proposed transaction with Infinity on July 14, 2023. All shareholders of record as of the close of business on May 24, 2023 are entitled to vote at the special meeting.
Shareholders who have questions or need assistance voting your shares, please contact Alliance Advisors, MEI’s proxy solicitor:
Source: BioSpace